AU2002232394A1 - Inhibition of alpha-2 hs glycoprotein (ahsg/fetuin) in obesity and insulin control of glucose homeostasis - Google Patents

Inhibition of alpha-2 hs glycoprotein (ahsg/fetuin) in obesity and insulin control of glucose homeostasis

Info

Publication number: AU2002232394A1
Authority: AU; Australia
Prior art keywords: ahsg; fetuin; glycoprotein; obesity; inhibition
Prior art date: 2000-10-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2002232394A

Other languages

English (en)

Inventor

Anton Scott Goustin

George Grunberger

Kai-Lin Catherine Jen

Suresh T. Mathews

Pothur R. Srinivas

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Wayne State University

Original Assignee

Wayne State University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-27

Filing date

2001-10-29

Publication date

2002-05-27

2001-10-29 Application filed by Wayne State University filed Critical Wayne State University

2002-05-27 Publication of AU2002232394A1 publication Critical patent/AU2002232394A1/en

Status Abandoned legal-status Critical Current

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
101150106303 AHSG gene Proteins 0.000 title 1
102000004877 Insulin Human genes 0.000 title 1
108090001061 Insulin Proteins 0.000 title 1
208000008589 Obesity Diseases 0.000 title 1
102000012005 alpha-2-HS-Glycoprotein Human genes 0.000 title 1
108010075843 alpha-2-HS-Glycoprotein Proteins 0.000 title 1
102000013361 fetuin Human genes 0.000 title 1
108060002885 fetuin Proteins 0.000 title 1
230000014101 glucose homeostasis Effects 0.000 title 1
230000005764 inhibitory process Effects 0.000 title 1
229940125396 insulin Drugs 0.000 title 1
235000020824 obesity Nutrition 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Toxicology (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Biophysics (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Child & Adolescent Psychology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)

AU2002232394A 2000-10-27 2001-10-29 Inhibition of alpha-2 hs glycoprotein (ahsg/fetuin) in obesity and insulin control of glucose homeostasis Abandoned AU2002232394A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US24344200P	2000-10-27	2000-10-27
US60/243,442		2000-10-27
PCT/US2001/042832 WO2002039923A2 (fr)	2000-10-27	2001-10-29	Inhibition de la glycoprotéine alpha-2 hs (ahsg/fétuine) en traitement de l'obésité et en régulation insulinique de l'homéostase glucosique

Publications (1)

Publication Number	Publication Date
AU2002232394A1 true AU2002232394A1 (en)	2002-05-27

Family

ID=22918793

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2002232394A Abandoned AU2002232394A1 (en)	2000-10-27	2001-10-29	Inhibition of alpha-2 hs glycoprotein (ahsg/fetuin) in obesity and insulin control of glucose homeostasis

Country Status (3)

Country	Link
US (2)	US20040198648A1 (fr)
AU (1)	AU2002232394A1 (fr)
WO (1)	WO2002039923A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2004257367A1 (en) *	2003-07-16	2005-01-27	Resverlogix, Inc.	Compounds and methods for downregulating the effects of TGF-beta
CA2654408C (fr)	2006-06-06	2018-05-08	Oleg Iliich Epshtein	Preparation medicamenteuse destinee au traitement peroral de l'exces ponderal, du diabete sucre et de maladies accompagnees d'une perturbation de la tolerance du glucose
US8962015B2 (en)	2007-09-28	2015-02-24	Sdg, Inc.	Orally bioavailable lipid-based constructs
US20100080773A1 (en)	2008-09-26	2010-04-01	Sdg, Inc.	Orally Bioavailable Lipid-Based Constructs
US9145453B2 (en) *	2007-09-28	2015-09-29	Sdg, Inc.	Orally bioavailable lipid-based constructs
US8846053B2 (en) *	2008-09-26	2014-09-30	Sdg, Inc.	Orally bioavailable lipid-based constructs
US11077173B2 (en)	2017-03-13	2021-08-03	Sdg, Inc.	Lipid-based nanoparticles and methods using same
AU2018236190B2 (en)	2017-03-13	2025-02-20	Sdg, Inc.	Lipid-based nanoparticles with enhanced stability
WO2022164854A2 (fr) *	2021-01-27	2022-08-04	Immunis, Inc.	Procédés de préparation de sécrétomes et leurs utilisations
CN115044682B (zh) *	2022-06-14	2024-08-30	兰州大学	与湖羊生长性状相关的分子标记、其检测方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991018924A1 (fr) *	1990-06-01	1991-12-12	W. Alton Jones Cell Science Center	Facteurs adipogenes de mammiferes
US5449757A (en) *	1990-06-01	1995-09-12	W. Alton Jones Cell Science Center	Mammalian adipogenic factors
AU667075B2 (en) *	1992-01-17	1996-03-07	W. Alton Jones Cell Science Center	Mammalian adipogenic factors

2001
- 2001-10-29 US US10/415,288 patent/US20040198648A1/en not_active Abandoned
- 2001-10-29 AU AU2002232394A patent/AU2002232394A1/en not_active Abandoned
- 2001-10-29 WO PCT/US2001/042832 patent/WO2002039923A2/fr not_active Ceased
2007
- 2007-07-05 US US11/773,883 patent/US20080050372A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20080050372A1 (en)	2008-02-28
WO2002039923A2 (fr)	2002-05-23
US20040198648A1 (en)	2004-10-07
WO2002039923A3 (fr)	2003-04-17

Similar Documents

Publication	Publication Date	Title
AU2002232394A1 (en)	2002-05-27	Inhibition of alpha-2 hs glycoprotein (ahsg/fetuin) in obesity and insulin control of glucose homeostasis
IL150260A0 (en)	2002-12-01	Propionic acid derivatives and their use in the treatment of diabetes and obesity
AU6272699A (en)	2000-04-17	Oximetry device and open oxygen delivery system
AU2002322394A1 (en)	2003-02-17	Method for treating diabetes and obesity
AU2001273151A1 (en)	2002-01-14	Human extracellular matrix and cell adhesion polypeptides
AU2003243551A1 (en)	2003-12-31	Use of an anti-endotoxin drug in the prevention and treatment of disease
AU2003228933A1 (en)	2003-11-17	Zonisamide use in obesity and eating disorders
AU2001256757A1 (en)	2002-02-14	Agents for preventing or ameliorating insulin resistance and/or obesity
AU2002356278A1 (en)	2003-07-09	Improvements in and relating to calf compression devices
AU2002353658A1 (en)	2003-06-30	Method of treating obesity, overweight, diabetes, or fluctuations in blood insuline or glucose levels
AU2001292658A1 (en)	2002-03-26	Method for treatment of insulin resistance in obesity and diabetes
AU2121200A (en)	2000-08-18	Improvements in or relating to sphygmomanometers and other devices
AU2003253629A1 (en)	2003-12-22	Large deletions in human brca1 gene and use thereof
AU2002352361A1 (en)	2003-06-23	Vibration control system and improvements in or relating to skis
AU2003252261A1 (en)	2004-02-25	System for measuring chromaticity in visible and invisible regions
AU2003238242A1 (en)	2003-12-31	Use of an anti-endotoxin drug in the prevention and treatment of disease
GB0210357D0 (en)	2002-06-12	Methods for regulating blood glucose and appetite suppression in type 2 diabetics
AU2001249310A1 (en)	2001-10-03	Prevention and/or treatment of diabetes mellitus by pharmacologically inhibitingpancreatic beta-cell o-linked protin glycosylation and/or pancreatic beta-cell p135 o-glycosylation
AU7792601A (en)	2002-02-05	Regulators of ppardelta(beta) and their use in the treatment of obesity and insulin resistance
AU4073299A (en)	1999-11-29	Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
GB0213596D0 (en)	2002-07-24	Improvements in and relating to catheter control
AU2003293500A1 (en)	2004-07-09	Lactoferrin in the reduction of pain
ZA200003985B (en)	2002-02-27	Cosmetic or dermatological use of 7-hydroxylated steroid alone and/or in combination with elastin derived peptides.
AU5076601A (en)	2001-07-03	Pulmonary delivery of ribavirin or levovirinTM for systemic and quasi-systemic treatment of disease
AU6330300A (en)	2001-01-30	Use of interleukin-6 in treatment of obesity and/or obesity associated disorders